Cel Sci (CVM) Current Deferred Revenue (2010 - 2019)
Cel Sci (CVM) posted Current Deferred Revenue of $125000.0 for Q3 2019, down 1.46% sequentially from $126849.0 in Q2 2019, and down 1.42% YoY from $126795.0 in Q3 2018.
Cel Sci (CVM) Current Deferred Revenue (2010 - 2019) Analysis & Trends
Cel Sci has reported Current Deferred Revenue for 9 years, with the latest figure at $125000.0 in Q3 2019.
- Quarterly Current Deferred Revenue fell 1.42% year-over-year to $125000.0 in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $125000.0 (down 1.42% YoY) and the FY2019 annual result came in at $125000.0, down 1.42% from the prior year.
- Current Deferred Revenue declined to $125000.0 in Q3 2019 per CVM's latest filing, from $126849.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $126849.0 in Q1 2019 and troughed at $125000.0 in Q3 2016.
- A 5-year average of $125918.2 and a median of $126501.0 in 2016 frame the typical range for Current Deferred Revenue.
- The widest YoY moves for Current Deferred Revenue: up 1.48% in 2019, down 1.42% in 2019.
- Over 5 years, Current Deferred Revenue stood at $126639.0 in 2015, then retreated by 1.29% to $125000.0 in 2016, then advanced by 1.24% to $126550.0 in 2017, then grew by 0.19% to $126795.0 in 2018, then retreated by 1.42% to $125000.0 in 2019.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $125000.0, $126849.0, and $126849.0 for Q3 2019, Q2 2019, and Q1 2019 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - |
| 10 | Cel Sci | 2.16 Mn | -4.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 125,000.00 |
| Jun 30, 2019 | 126,849.00 |
| Mar 31, 2019 | 126,849.00 |
| Dec 31, 2018 | 126,795.00 |
| Sep 30, 2018 | 126,795.00 |
| Jun 30, 2018 | 126,795.00 |
| Mar 31, 2018 | 125,000.00 |
| Dec 31, 2017 | 126,550.00 |
| Sep 30, 2017 | 125,000.00 |
| Jun 30, 2017 | 125,000.00 |
| Mar 31, 2017 | 125,000.00 |
| Dec 31, 2016 | 125,000.00 |
| Sep 30, 2016 | 125,000.00 |
| Jun 30, 2016 | 126,501.00 |
| Sep 30, 2015 | 126,639.00 |
| Mar 31, 2013 | 126,545.00 |
| Dec 31, 2012 | 126,500.00 |
| Sep 30, 2012 | 126,500.00 |
| Jun 30, 2012 | 126,500.00 |
| Mar 31, 2012 | 126,500.00 |